Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
DN

NYSE · DNA

Ginkgo Bioworks Holdings, Inc.

Healthcare · Biotechnology

$11.21

Down-$1.53 (-12.01%)

Updated Nov 1, 2026, 12:57 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
539.91M
P/E ratio
-1.62
Dividend yield
0.00%
52-week range
$5.37 – $18.22
Volume
2.73M
Avg. volume
1.4M

Price performance · DNA

DNA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

DNA closed at $11.21 after 20 trading sessions, down 25.17% for the selected period.

Last close
$11.21
Period change
-25.17%
Period low
$9.71
Period high
$14.98
Daily close
View OHLC price history
DNA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$12.12$12.65$10.60$11.212.73M
Oct 29, 2026$13.08$13.97$12.72$12.742.9M
Oct 28, 2026$11.16$13.67$11.16$13.323.78M
Oct 27, 2026$10.12$11.69$9.87$11.273.01M
Oct 26, 2026$9.96$10.11$9.69$10.021.27M
Oct 23, 2026$9.61$9.99$9.4307$9.991.16M
Oct 22, 2026$9.69$10.14$9.50$9.711.98M
Oct 21, 2026$9.88$10.10$9.6121$10.011.78M
Oct 20, 2026$10.12$10.38$9.85$9.862.49M
Oct 19, 2026$10.38$10.50$9.76$10.072.48M
Oct 16, 2026$11.62$11.80$10.125$10.273.55M
Oct 15, 2026$11.07$11.80$10.40$11.762.33M
Oct 14, 2026$11.42$12.07$11.24$11.531.76M
Oct 13, 2026$11.79$12.4499$11.51$11.761.86M
Oct 12, 2026$12.69$12.8238$11.26$11.792.6M
Oct 9, 2026$11.76$13.555$11.4802$13.004.52M
Oct 8, 2026$10.92$11.41$10.61$11.343.21M
Oct 7, 2026$11.805$11.9466$10.81$11.476.46M
Oct 6, 2026$15.08$18.22$12.11$12.4113.14M
Oct 5, 2026$12.50$15.48$12.48$14.987.69M

Latest DNA news

The latest Smart Investors Daily articles mentioning DNA.

Stock researchCompany · Overview

DNA research

Overview

Company profile and research snapshot.

Company profile

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
DNA recent ratings
DateFirmRatingTarget
Oct 13, 2026TD CowenHold—
Sep 4, 2026BTIGSell—
Aug 7, 2026TD CowenHold—
Mar 12, 2026BTIGSell—
Jan 8, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

What Ginkgo Bioworks Bears Saw Before The Fall

Ginkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup. For Ginkgo Bioworks shareholders, the loss over the past year was 26.4%, including dividends. If you had committed fresh capital a year ago on the bullish and bearish analyst cases published in late 2025, how do these new lab partnerships compare with a net margin that moved further into the red, and what...

Yahoo · Oct 14, 2026

Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand

The latest analyst update on Ginkgo Bioworks Holdings includes a higher fair value estimate of US$8 and at least one price target set at US$11, which points to a reassessment of what investors might be willing to pay for the stock. That shift is closely linked to recent commentary that combines enthusiasm about life science tools and AI-linked demand with a more cautious view on the company’s execution and near term fundamentals. Read on to see how these price targets fit into the evolving...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By